Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate

Fukasawa, Lucila O; Gorla, Maria Maria Cecília O; Schenkman, Rocilda P F; Garcia, Ligiane R; Carneiro, Sylvia M; Raw, Isaias; Tanizaki, Martha M.
Vaccine ; 17(23-24): 2951-2958, 1999.
Artículo en Inglés | SES-SP, SESSP-IBPROD, SES-SP, SESSP-IBACERVO | ID: biblio-1068324

Documentos relacionados

  1. 4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp.
  2. [Research progress on immunogenicity evaluation of serogroup B meningococcal vaccine].
  3. MenAfriNet: A Network Supporting Case-Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa.
  4. Structure of a protective epitope reveals the importance of acetylation of <i>Neisseria meningitidis</i> serogroup A capsular polysaccharide.
  5. An overview of bacterial meningitis epidemics in Africa from 1928 to 2018 with a focus on epidemics "outside-the-belt".
  6. The next chapter for group B meningococcal vaccines.
  7. A Fluorinated Sialic Acid Vaccine Lead Against Meningitis B and C.
  8. Trends in Neisseria meningitidis serogroups amongst patients with suspected cerebrospinal meningitis in the meningitis belt of Ghana: a 5-year retrospective study.
  9. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.
  10. Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010-2016.